ライフサイエンスコーパス: package insert

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 this information was added to the linezolid package insert.

2 cts of this drug which was not listed by its package insert.

3 try for ibritumomab tiuxetan and the product package insert.

4 some of which are currently reflected in the package insert.

5 s for the bortezomib dosages were within the package insert.

6 impairment were added to the zoledronic acid package insert.

7 n response or lack thereof should follow the package insert.

8 included in the 'indications' portion of the package insert.

9 ol procedures outlined in the manufacturer's package insert.

10 ng and after PCI, defined in accordance with package inserts.

11 for tuberculosis diagnostics reported in 19 package inserts against estimates in published meta-anal

12 who received dexamethasone according to the package insert) and granisetron (2 mg orally) on days 2-

13 nts taking antidepressants; a boxed warning, package insert, and medication guide were implemented in

14 m the drug-effect relationships found in FDA package inserts as recorded in the SIDER database.

15 eportedly produces alopecia according to the package insert, but clinical and histologic descriptions

16 filled the criteria for SL8 according to the package insert, but only 193 (57.2%) were eventually tre

17 red renal function are reflected in a recent package insert change by the Food and Drug Administratio

18 e color results (negative result but with no package insert color visible), and 8,234 specimens were

19 The information provided in the package insert facilitates physician education and provi

20 approved drugs, clinicians must consult the package insert for detailed prescribing information, lis

21 t use of cerivastatin and gemfibrozil to the package insert for more than 18 months.

22 es in published meta-analyses and found that package inserts generally report overoptimistic accuracy

23 f the 70 FDA new or revised labels, only six package inserts include PRO data.

24 F BDG testing was performed according to the package insert instructions for serum samples, and resul

25 ly identical to those obtained following the package insert instructions.

26 use not described in the indications of the package insert is considered 'off-label'.

27 eri test performance published through 1998, package insert labeling from FDA-cleared test kits for B

28 definitive geriatric dose recommended in the package inserts made available to the public.

29 According to package inserts, metformin is contraindicated in diabeti

30 The package inserts of all approved antipsychotics contain p

31 Laboratorians and clinicians often rely on package inserts of diagnostic tests to assess their accu

32 However, package inserts of most tests approved by the U.S. Food

33 edict DDIs by integrating SEs extracted from package inserts of prescription drugs, SEs extracted fro

34 ADR information for oncology drugs from package insert (PI) revisions, so-called Dear Doctor let

35 ronic databases, print references, published package inserts, product packages, and direct communicat

36 o impact performance indices compared to the package insert protocol (P >/= 0.31), provided accurate

37 Package insert protocol instructions were followed.

38 The US EFV package insert recommends an EFV dose increase for patie

39 The current package insert recommends an examination period of 3 day

40 In this study, we systematically collected package insert-reported AEs associated with CVDs used in

41 ty control (QC) ranges listed in the product package insert require an adjusted range by approximatel

42 specimen stability for use beyond the Aptima package insert specifications for temperature and durati

43 Compared with the current package insert, we found differences in median absorbed

44 Bortezomib therapy was administered per package insert with plasmapheresis performed immediately

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。